Clobazam

Ng, Yu-Tze; Collins, Stephen

doi:10.1016/j.nurt.2006.11.002

Cited by 90 publications

(99 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In children with Lennox-Gastaut syndrome, lamotrigine and topiramate is efficient in atonic and tonic clonic seizures and valproic acid is efficient in drop attack, atypical absence and myoclonic seizures (19)(20)(21). In studies performed in patients with Lennox-Gastaut syndrome, it has been reported that clobazamine leads to sedation with a lower rate, decreases seizures by 50-100% in more than 50% of the patients, maintains its efficiency of 42% after more than one year of use and provides seizure-free state for more than 6 months in 72% of the patients (22,23). It is reported that seizures of the patients with LGS are decreased with intravenous gammaglubulin treatment (24).…”

Section: Discussionmentioning

confidence: 99%

Lennox-Gastaut sendromlu hastaların klinik özellikleri ve uzun süreli seyri

Ekici¹,

Yarar²,

Yakut³

et al. 2012

tpa

View full text Add to dashboard Cite

Aim:The aim of this study was to retrospectively evaluate clinical features, treatment and prognosis of 20 patients followed up as Lennox-Gastaut Syndrome in ESOGU in the Division of Pediatric Neurology. Material and Method: Multiple different types of seizure, diffuse spike-wave pattern(<3 Hz) on electroencephalogram, psychomotor retardation were the diagnostic criteria for Lennox-Gastaut Syndrome. The patients who had no etiologic reason were described as the idiopathic type. Prenatal, natal and postnatal risk factors, seizure and clinical features, neurodevelopmental status, treatment and prognostic features were evaluated. Results: Thirteen patients were female, seven were male; male/female ratio was 1,9. Nineteen patients were described as the symptomatic type. Hypoxic ischemic encephalopthy was the most common risk factor. Sixty percent of the patients had a history of infantile spasms. Generalized tonic, generalized tonic clonic and atonic drop attacks were the most common seizure types. Speech impairment and microcephaly were the most frequently seen neurologic findings. Diffuse spike-wave activity (1-3 Hz/s) on EEG, bioelectrical status epilepticus and 9-14 Hz/s fast activity discharges were the most commonly seen discharges. The most common neuroimaging finding was cerebral atrophy. Sixty percent of the patients suffered from a large number of seizures per day despite multiple antiepileptic drugs. The most commonly used antiepileptic drugs were valproate sodium, clobazam, lamotrigine and topiramate. Conclusions: The prognosis of Lennox-Gestaut Syndrome is poor due to either recurrent seizures or mental deterioration. Seizure control can not be provided despite the use of multiple anti-epileptic drugs. New antiepileptic drugs are needed. (Turk Arch Ped 2012; 47: 49-54)

show abstract

Section: Discussionmentioning

confidence: 99%

Lennox-Gastaut sendromlu hastaların klinik özellikleri ve uzun süreli seyri

Ekici¹,

Yarar²,

Yakut³

et al. 2012

tpa

View full text Add to dashboard Cite

show abstract

“…More than 70% of administered clobazam is demethylated to yield N-desmethylclobazam (N-clobazam), a pharmacologically active metabolite that reaches higher plasma concentrations than clobazam and may substantially contribute to the efficacy and safety of long-term clobazam therapy [38,39]. This demethylation is facilitated by CYP3A4, CYP2C19 and CYP2B6, and the subsequent inactivation of N-clobazam to 4'-hydroxynorclobazam is catalyzed primarily by CYP2C19 [40].…”

Section: Clobazam Therapymentioning

confidence: 99%

The clinical impact of cytochrome P450 polymorphisms on anti-epileptic drug therapy

Saruwatari

Ishitsu

Shioiri

et al. 2010

E&S

View full text Add to dashboard Cite

“…CLB, a 1,5-benzodiazepine, enhances GABAergic activity by binding to the α subunit of the GABA A receptor and increasing the frequency of chloride channel conductance by allosteric activation of the GABA A receptor [21]. Moreover, CLB increases the expression of glutamate transporter protein 1 and GABA transporter protein 3 in the brain [22].…”

Section: Discussionmentioning

confidence: 99%

Additive Interactions between 1-Methyl-1,2,3,4-Tetrahydroisoquinoline and Clobazam in the Mouse Maximal Electroshock-Induced Tonic Seizure Model - An Isobolographic Analysis for Parallel Dose-Response Relationship Curves

Andres-Mach¹,

Haratym-Maj²,

Zagaja³

et al. 2014

Pharmacology

View full text Add to dashboard Cite

Background: The aim of this study was to characterize the anticonvulsant effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTHIQ) in combination with clobazam (CLB) in the mouse maximal electroshock-induced seizure (MES) model. Methods: The anticonvulsant interaction profile between 1-MeTHIQ and CLB in the mouse MES model was determined using an isobolographic analysisfor parallel dose-response relationship curves. Results: Electroconvulsions were produced in albino Swiss mice by a current (sine wave, 25 mA, 500 V, 50 Hz, 0.2-second stimulus duration) delivered via auricular electrodes by a Hugo Sachs generator. There was an additive effect of the combination of 1-MeTHIQ with CLB (at the fixed ratios of 1:3, 1:1 and 3:1) in the mouse MES-induced tonic seizure model. Conclusions: The additive interaction of the combination of 1-MeTHIQ with CLB (at fixed-ratios of 1:3, 1:1 and 3:1) in the mouse MES model seems to be pharmacodynamic in nature and worth of considering in further clinical practice.

show abstract

Clobazam

Cited by 90 publications

References 45 publications

Lennox-Gastaut sendromlu hastaların klinik özellikleri ve uzun süreli seyri

Lennox-Gastaut sendromlu hastaların klinik özellikleri ve uzun süreli seyri

The clinical impact of cytochrome P450 polymorphisms on anti-epileptic drug therapy

Additive Interactions between 1-Methyl-1,2,3,4-Tetrahydroisoquinoline and Clobazam in the Mouse Maximal Electroshock-Induced Tonic Seizure Model - An Isobolographic Analysis for Parallel Dose-Response Relationship Curves

Contact Info

Product

Resources

About